Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Theravance Biopharma, Inc. (NASDAQ:TBPH) has received an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $21.8333.

A number of analysts recently issued reports on TBPH shares. Weiss Ratings cut Theravance Biopharma from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 8th. Oppenheimer cut Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. Zacks Research raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Thursday, March 19th. B. Riley Financial raised their price target on Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a report on Tuesday, April 7th. Finally, TD Cowen raised their price target on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a report on Monday, March 23rd.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the sale, the senior vice president directly owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This trade represents a 11.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.65% of the stock is owned by corporate insiders.

Institutional Trading of Theravance Biopharma

Several hedge funds have recently modified their holdings of TBPH. AQR Capital Management LLC acquired a new stake in shares of Theravance Biopharma in the 1st quarter valued at approximately $101,000. Jane Street Group LLC increased its stake in Theravance Biopharma by 169.2% in the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock valued at $1,258,000 after purchasing an additional 88,540 shares in the last quarter. Creative Planning purchased a new position in Theravance Biopharma in the 2nd quarter valued at approximately $139,000. American Century Companies Inc. increased its stake in Theravance Biopharma by 6.8% in the 2nd quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock valued at $1,009,000 after purchasing an additional 5,794 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Theravance Biopharma by 12.4% in the 2nd quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,789 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Stock Performance

TBPH opened at $16.25 on Wednesday. Theravance Biopharma has a one year low of $9.10 and a one year high of $21.03. The company has a market cap of $837.69 million, a P/E ratio of 7.39 and a beta of 0.19. The business’s 50-day simple moving average is $15.85 and its 200-day simple moving average is $17.51.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The business had revenue of $17.70 million during the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. As a group, analysts predict that Theravance Biopharma will post 0.95 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.